Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Zymeworks BC Inc | TG:ZA8 | Tradegate | Ordinary Share |
| Price Change | % Change | Share Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|
| 0.00 | 0.00% | 13.40 | 0.00 | 07:15:29 |
| Bid Price | Offer Price | High Price | Low Price | Open Price | |
|---|---|---|---|---|---|
| 13.40 | 13.50 | ||||
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| - |
| Last Trade Time | Trade Type | Trade Size | Trade Price | Currency |
|---|---|---|---|---|
| - | 0 | 13.40 | EUR |
| Date | Time | Source | Headline |
|---|---|---|---|
| 21/11/2024 | 11:05 | UKREG | Zymeworks Announces Participation in Upcoming Investor Conferences |
| 21/11/2024 | 11:00 | UKREG | FDA Grants U.S. Approval of Ziihera® (zanidatamab-hrii) for the Treatment.. |
| 05/11/2024 | 11:00 | UKREG | Zymeworks Announces First Patient Dosed in Phase 1 Clinical Trial.. |
| 29/10/2024 | 10:00 | UKREG | Zymeworks Announces Participation in Upcoming Investor Conferences |
| 25/10/2024 | 10:00 | UKREG | Zymeworks Presents New Preclinical Data on Antibody-Drug Conjugate Programs.. |
| 21/10/2024 | 10:00 | UKREG | Zymeworks Announces First Patient Dosed in Phase 1 Clinical Trial.. |
| 18/9/2024 | 10:00 | UKREG | Zymeworks to Present Preclinical Data on Antibody-Drug Conjugate Programs.. |
| 22/8/2024 | 10:30 | UKREG | Zymeworks Announces Participation in Upcoming Investor Conferences |
| 01/8/2024 | 20:10 | UKREG | Zymeworks Announces Share Repurchase Program of up to $60 Million of its.. |
| 25/7/2024 | 20:30 | UKREG | Zymeworks Appoints Leone Patterson as Chief Business and Financial Officer |
Zymeworks BC (ZA8) Share Charts1 Year Zymeworks BC Chart |
|
1 Month Zymeworks BC Chart |
Intraday Zymeworks BC Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
